✦ LIBER ✦

Atorvastatin added to interferon beta for relapsing multiple sclerosis: a randomized controlled trial

✍ Scribed by Kamm, Christian Philipp; El-Koussy, Marwan; Humpert, Sebastian; Findling, Oliver; Bredow, Ferdinand; Burren, Yuliya; Schwegler, Guido; Schött, Dagmar; Donati, Filippo; Müller, Martin; Goebels, Norbert; Müller, Felix; Slotboom, Johannes; Tettenborn, Barbara; Kappos, Ludwig; Naegelin, Yvonne; Mattle, Heinrich Paul

Book ID: 118784382
Publisher: Springer
Year: 2012
Tongue: English
Weight: 251 KB
Volume: 259
Category: Article
ISSN: 0340-5354
DOI: 10.1007/s00415-012-6513-7

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

OPL102 Subgroup analyses from SENTINEL:

OPL102 Subgroup analyses from SENTINEL: a randomized controlled trial of natalizumab (Tysabri®) and interferon beta-1a (AVONEX®) in relapsing multiple sclerosis (MS)

📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 130 KB

Intramuscular interferon beta-1a for dis

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis

✍ Dr. Lawrence D. Jacobs; Diane L. Cookfair; Richard A. Rudick; Robert M. Herndon; 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 980 KB

A phase I clinical trial of human recomb

A phase I clinical trial of human recombinant beta interferon in relapsing-remitting multiple sclerosis

✍ J.I. Greenstein; R.L. Knobler; K.P. Johnson; S.G. Marcus; H.S. Panitch; F.D. Lub 📂 Article 📅 1987 🏛 Elsevier Science 🌐 English ⚖ 35 KB

Simvastatin as add-on therapy to interfe

Simvastatin as add-on therapy to interferon beta-1a for relapsing-remitting multiple sclerosis (SIMCOMBIN study): a placebo-controlled randomised phase 4 trial

✍ Per Soelberg Sorensen; Jan Lycke; Juha-Pekka Erälinna; Astrid Edland; Xingchen W 📂 Article 📅 2011 🏛 The Lancet 🌐 English ⚖ 349 KB

OPL101 SENTINEL: a randomized controlled

OPL101 SENTINEL: a randomized controlled trial of natalizumab (tysabri®) and interferon beta-1a (AVONEX®) in relapsing multiple sclerosis (MS). Magnetic resonance imaging (MRI) results

📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 130 KB

Alemtuzumab versus interferon beta 1a as

Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial

✍ Jeffrey A Cohen; Alasdair J Coles; Douglas L Arnold; Christian Confavreux; Edwar 📂 Article 📅 2012 🏛 The Lancet 🌐 English ⚖ 334 KB